Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to dolutegravir plus lamivudine in virologically suppressed HIV-1 infected adults
2015-004401-17Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dolutegravir and lamivudine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Primary virologic failure endpoint at Week 48. Started Jan 2018; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-004401-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004401-17.